Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
The DOI matches its Crossref record; 124 of the 125 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is the most common primary malignancy in the brain and confers a uniformly poor prognosis. Despite decades of research on the topic, limited progress has been made to improve the poor survival associated with this disease. GBM arises de novo (primary GBM) or via dedifferentiation of lower grade glioma (secondary GBM). While distinct mutations are predominant in each subtype, alterations of tumor suppressor p53 are the most common, seen in 25-30 % of primary GBM and 60-70 % of secondary GBM. Various roles of p53 that protect against neoplastic transformation include modulation of cell cycle, DNA repair, apoptosis, senescence, angiogenesis, and metabolism, resulting in an extremely complex signaling network. Mutations of p53 in GBM are most common in the DNA-binding domain, namely within six hotspot mutation sites (codons 175, 245, 248, 249, 273, and 282). These alterations generally result in loss-of-function, gain-of-function, and dominant-negative mutational effects for p53, however, the distinct effect of these mutation types in GBM pathogenesis remain unclear. Signaling alterations downstream from p53 (e.g., MDM2, MDM4, INK4/ARF), p53 isoforms (e.g., p63, p73), and microRNAs (e.g., miR-34) also play critical roles in modulating the p53 pathway. Despite novel mouse models of GBM showing that p53 combined with other mutation generate tumors de novo, the role of p53 as a molecular marker of GBM remains controversial with most studies failing to show an association with prognosis. Regarding treatment in GBM, p53 targeted-gene therapy and vaccinations have reached phase I clinical trials while therapeutic drugs are still in preclinical development. This review aims to discuss the most recent findings regarding the impact of p53 mutations on GBM pathogenesis, prognosis, and treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDM2 targets p53 for degradation, acting as a negative regulator [27,41].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [27]
In the citing paper
“p53 inactivation is correlated with a more invasive [30], less apoptotic [31], more proliferative [27], and more stem-like [28] phenotype.”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [27]
In the citing paper
“Although mut-p53 has been correlated to poorer prognosis in breast and other cancers [32], the mutational status of TP53 and its various pathway elements (ARF-MDM2/4) has not been correlated with survival in GBM, despite the high mutation frequency [27,32,33,34].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [27]
In the citing paper
“MDM2 amplifications have not been shown to correlate with GBM survival and/or prognosis [27,32,33,34].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [27]
In the citing paper
“Amplification of MDM2 and MDM4 can inactivate p53, leading to loss of various tumor suppressor functions including growth arrest, apoptosis, DNA repair, and senescence [27,41].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [27]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“Recent studies have demonstrated the transformation of differentiated fibroblasts by adenovirus-mediated transfection of oct4, sox2, klf4, and c-Myc into induced pluripotent stem cells (iPSC) that possess a multipotent state and potential to differentiate along a variety of cell lineages [62].”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“Inactivation of p53 can also occur by multiplication of the MDM2 gene (an E3 ubiquitin ligase which targets p53 for degradation), viral infection, deletion of the p14 gene, and mislocalization of p53 to the cytoplasm [12].”
BackgroundAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 6×
“Approximately 95 % of all p53 mutations occur in the core DNA-binding domain, 28 % of all mutations occur at p53 hotspot mutation sites (codons 175, 245, 248, 249, 273, and 282), and 75 % of all mutations are missense mutations [5, 14].”
BackgroundInfluentialIsolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma
Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., Fiocco, R., Foroni, C., Dimeco, F., & Vescovi, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1364 · Cited by 2,570 · cited 1×
“These findings are relevant in the context of recently discovered CSCs in GBM that may account for this tumor’s origin, proliferative capacity, and recurrence [9, 61].”
BackgroundCrystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 1×
“Hotspot mutations are located near the protein-DNA interface and most commonly including contact mutants/class I mutation (R248, R273) that interact with DNA, and structural mutants/class II mutations (R175, R245, R249, R282) that play critical roles in stabilizing the structure of the DNAbinding interface [13, 29].”
BackgroundChromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
Cited by
Epidemiology of Glioblastoma Multiforme–Literature Review
Grochans, S., Cybulska, A. M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., & Baranowska-Bosiacka, I. (2022) · Cancers · doi:10.3390/cancers14102412 · Cited by 630
“The inactivation of p53 correlates with increased invasiveness [49], decreased cell apoptosis [50], and increased proliferation [51].”
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
“It is commonly activated in response to DNA damage, genotoxicity, oncogene activation, aberrant growth signals, and hypoxia, all of which are events that can be encountered during carcinogenesis [27].”
BackgroundInfluentialEmerging treatment strategies for glioblastoma multiforme
Carlsson, S. K., Brothers, S. P., & Wahlestedt, C. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201302627 · Cited by 365
“…may limit the therapeutic value of this target (Heimberger et al , 2005). p 53 and PTEN p53 is a well-known tumor suppressor protein that plays a fundamental role in the formation of high-grade tumors (England et al , 2013). p53 initiates DNA repair, or apoptosis if DNA damage is irrep-arable.”
Emerging Therapies for Glioblastoma
Thomas, A. A., Brennan, C. W., DeAngelis, L. M., & Omuro, A. M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1701 · Cited by 167
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies
Garber, S. T., Hashimoto, Y., Weathers, S.-P. S., Xiu, J., Gatalica, Z., Verhaak, R. G. W., Zhou, S., Fuller, G. N., Khasraw, M., de Groot, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now132 · Cited by 144
Metadata
- Authors
- England, B., Huang, T., & Karsy, M.
- Affiliations
- New York Medical College (US)
- Corresponding author
- Karsy, Michael
- Venue
- Tumor Biology
- Published
- 2013-06-05
- Volume
- 34
- Issue
- 4
- Pages
- 2063-2074
- ISSN
- 1010-4283 (ISSN-L)
- 1423-0380
- OpenAlex
- W2004432187
- Cited by
- 163
- References
- 125
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 17 · 2023: 9 · 2022: 15 · 2021: 18 · 2020: 12 · 2019: 8 · 2018: 6 · 2017: 13 · 2016: 16 · 2015: 13 · 2014: 20 · 2013: 1
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Tumor Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- glioblastoma, p53, tumor suppressor, TP53 mutation, mutational hotspots, loss of function, gain-of-function, dominant-negative p53, MDM2, MDM4, p53 isoforms, miR-34, p63, p73, prognosis, cancer vaccination
- MeSH terms
- Animals, Brain Neoplasms, Glioblastoma, Humans, Prognosis, Signal Transduction, Tumor Suppressor Protein p53, Protein Isoforms, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. https://app.cochat.ai/papers/10.1007/s13277-013-0871-3
- The paper
- England, B., Huang, T., & Karsy, M. (2013). Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumor Biology. https://doi.org/10.1007/s13277-013-0871-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.